

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.

康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

THE FIRST GRANT AND THE RESERVED GRANT OF PART OF RESTRICTED SHARES TO THE PARTICIPANTS UNDER THE 2021 RESTRICTED SHARE INCENTIVE SCHEME

References are made to the announcement dated August 20, 2021 and the circular (the “**Circular**”) dated August 26, 2021 of CanSino Biologics Inc. (the “**Company**”), in relation to, among others thing, the 2021 restricted share incentive scheme of the Company (the “**Incentive Scheme**”), and the announcement in relation to the poll results of the 2021 second extraordinary general meeting (the “**EGM**”), the 2021 First Class Meeting of H Shareholders (the “**H Shares Class Meeting**”) and the 2021 First Class Meeting of A Shareholders (the “**A Shares Class Meeting**”, together with the H Shares Class Meeting, the “**Class Meetings**”) dated September 10, 2021. Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The board of director of the Company (the “**Board**”) is pleased to announce that, the implementation of the Incentive Scheme by the Company has been approved by the Shareholders at the EGM and the Class Meetings, and the Board is authorized to, among other things, determine the Grant Date, grant the Restricted Shares to the Participants after the relevant conditions having been satisfied and handle all matters necessary for the grant of Restricted Shares. As the conditions for the grant of Restricted Shares under the First Grant and the Reserved Grant as set out in the Incentive Scheme have been satisfied, pursuant to the authorization granted by the Shareholders at the EGM and the Class Meetings, the Board has resolved at the meeting of the Board held on September 10, 2021 to approve:

- (a) the grant of an aggregate of 875,330 Restricted Shares, representing approximately 0.3537% of the total share capital of the Company as of the date of this announcement, to 388 Participants at the Grant Price of RMB209.71 per A Share on the Grant Date, being September 10, 2021, under the First Grant pursuant to the Incentive Scheme. The First Grant originally involved the grant of 880,200 Restricted Shares in total to 391 Participants, among which, 3 Participants have waived to subscribe for the Restricted Shares under the First Grant due to reasons including resignation or tendering resignation application and thus the grant of 4,870 Restricted Shares waived by them are cancelled. Accordingly, the number of Restricted Shares under the First Grant has been adjusted from no more than 880,200 Restricted Shares to no more than 875,330 Restricted Shares; and

- (b) the grant of 49,660 Restricted Shares, representing approximately 0.0201% of the total share capital of the Company as of the date of this announcement and approximately 22.5676% of the total Restricted Shares under the Reserved Grant, to 7 Participants, at the Grant Price of RMB209.71 per A Share on the Grant Date, under the Reserved Grant pursuant to the Incentive Scheme.

After the adjustment to the number of Restricted Shares under the First Grant as set out above, the total number of Restricted Shares to be granted under the Incentive Scheme has been adjusted from no more than 1,100,250 Restricted Shares to no more than 1,095,380 Restricted Shares. Therefore, the total funds to be raised under the Incentive Scheme will be no more than RMB229,712,139.8, being the aggregated amount to be paid by Participants to subscribe for no more than 1,095,380 Restricted Shares under the Incentive Scheme at the Grant Price (subject to adjustment). There will be no change to the proposed use of proceeds as set out in the paragraph headed “Total funds to be raised and the proposed use of proceeds” in the Circular.

The First Grant and the above Reserved Grant under the Incentive Scheme do not involve the grant of Restricted Shares to connected persons of the Company (or any of its subsidiaries) and therefore is not subject to the notification, announcement and shareholder approval requirements under Chapter 14A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Listing Rules**”). In the event that any grantee of the remaining Restricted Shares under the Reserved Grant is a connected person of the Company (or any of its subsidiaries), the Company will comply with the relevant requirements under the Hong Kong Listing Rules as and when appropriate.

No Restricted Shares will be issued by the Company to the Participants under the Incentive Scheme until the attribution period ends. Further details of the Incentive Scheme, the issue and grant of the Restricted Shares (including the First Grant and the Reserved Grant) and the full text of the Incentive Scheme and the Assessment Management Measures are set out in the Circular.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, September 10, 2021

As of the date of this announcement, the Board comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.